anagrelidum aop 0,5 mg kapsułki twarde
aop orphan pharmaceuticals ag - anagrelidum - kapsułki twarde - 0,5 mg
anagrelid nordic 0,5 mg tabletki
nordic group b.v. - anagrelidum - tabletki - 0,5 mg
anagrelid nordic 0,75 mg tabletki
nordic group b.v. - anagrelidum - tabletki - 0,75 mg
anagrelid nordic 1 mg tabletki
nordic group b.v. - anagrelidum - tabletki - 1 mg
retsevmo
eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - Środki przeciwnowotworowe - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.